NCT06844669 2026-03-03
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Washington University School of Medicine
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07029503 2026-02-24
SCARF-1
Karolinska Institutet
Phase 2 Recruiting
NCT07245069 2025-11-24
Alpaca
University Medical Centre Ljubljana
Phase 2 Recruiting
NCT02943590 2025-05-15
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
Massachusetts General Hospital
Phase 2 Completed
NCT04680442 2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2 Recruiting
NCT06645691 2024-12-06
POLARIC-13
National Heart Centre Singapore
Phase 2 Recruiting
NCT06092606 2023-10-23
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Monyan Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Unknown
NCT05732051 2023-03-17
NARNIA
University Hospital, Akershus
Phase 2 Recruiting
NCT03186404 2022-02-08
SPARE-HF
University Health Network, Toronto
Phase 2 Unknown
NCT03557255 2018-06-14
Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries
National Cancer Institute, Egypt
Phase 2 Completed
NCT01434134 2014-10-22
PRADA
University Hospital, Akershus
Phase 2 Completed